Body mass index influences the response to infliximab in ankylosing spondylitis.

Arthritis Research & Therapy
Sébastien OttavianiPhilippe Dieudé

Abstract

The excess of adipose tissue in obese individuals may have immunomodulating properties and pharmacokinetic consequences. The aim of this study was to determine whether body mass index (BMI) affects response to infliximab (IFX) in ankylosing spondylitis (AS) patients. In 155 patients retrospectively included with active AS, the BMI was calculated before initiation of IFX treatment (5 mg/kg intravenously). After 6 months of treatment, changes from baseline in BASDAI, Visual Analogue Scale (VAS) pain, C-reactive protein (CRP) level, and total dose of nonsteroidal antiinflammatory drug (NSAID) were dichotomized with a threshold corresponding to a decrease of 50% of initial level of the measure, into binary variables assessing response to IFX (BASDAI50, VAS50, CRP50, NSAID50). Whether the BMI was predictive of the response to IFX therapy according to these definitions was assessed with logistic regression. Multivariate analysis found that a higher BMI was associated with a lower response for BASDAI50 (P = 0.0003; OR, 0.87; 95% CI (0.81 to 0.94)), VAS50 (P < 0.0001; OR, 0.87; 95% CI (0.80 to 0.93)); CRP50 (P = 0.0279; OR, 0.93; 95% CI (0.88 to 0.99)), and NSAID50 (P = 0.0077; OR, 0.91; 95% CI (0.85 to 0.97)), criteria. According to t...Continue Reading

References

May 2, 2001·Journal of Hypertension·A M SharmaJ Scholze
Feb 5, 2005·Arthritis and Rheumatism·Désirée van der HeijdeUNKNOWN Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group
Sep 26, 2006·Nature Reviews. Immunology·Herbert Tilg, Alexander R Moschen
Apr 11, 2008·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Rosita SaracenoSergio Chimenti
Sep 24, 2008·Dermatology : International Journal for Clinical and Investigative Dermatology·Luigi NaldiRosanna Cuscito
Oct 14, 2008·Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition·Dawn WieseDouglas Seidner
May 1, 2009·Arthritis and Rheumatism·Roman KrzysiekUNKNOWN French Ankylosing Spondylitis Infliximab Network
May 26, 2009·Arquivos brasileiros de endocrinologia e metabologia·Nivaldo Ribeiro VillelaEliete Bouskela
Jul 1, 2009·Fundamental & Clinical Pharmacology·Christos S DerdemezisDimitrios N Kiortsis
Dec 1, 2009·Nature Reviews. Rheumatology·Ulf Müller-Ladner, Elena Neumann
Jan 14, 2010·Clinical Pharmacokinetics·Michael J HanleyDavid J Greenblatt
Aug 17, 2010·British Journal of Anaesthesia·L I CortínezP Sepulveda
Feb 1, 2011·Arthritis and Rheumatism·Ruth KlaasenPaul P Tak
Mar 16, 2011·Annals of the Rheumatic Diseases·Nathan VastesaegerJürgen Braun
Apr 16, 2011·Journal of the European Academy of Dermatology and Venereology : JEADV·L Puig

❮ Previous
Next ❯

Citations

Mar 22, 2013·World Journal of Gastrointestinal Pharmacology and Therapeutics·John McConnellBeth Woodward
Jan 11, 2014·Rheumatology·Elisa GremeseGianfranco Ferraccioli
Aug 13, 2014·Advances in Therapy·Marcello GovoniMaurizio Rossini
Dec 10, 2014·Best Practice & Research. Clinical Rheumatology·Andreas M Reimold, Vinod Chandran
Feb 15, 2016·Joint, Bone, Spine : Revue Du Rhumatisme·Clément PratiDaniel Wendling
Jan 15, 2014·Joint, Bone, Spine : Revue Du Rhumatisme·Daniel WendlingUNKNOWN French Society for Rheumatology (SFR)
Dec 11, 2014·Journal of the European Academy of Dermatology and Venereology : JEADV·J SpertinoL Puig
Mar 8, 2016·Expert Review of Clinical Immunology·Barbara TolussoElisa Gremese
Jul 18, 2015·Joint, Bone, Spine : Revue Du Rhumatisme·Sébastien OttavianiPhilippe Dieudé
Jun 17, 2014·Journal of Korean Medical Science·Hye Won KimEun Young Lee
Mar 28, 2016·The Korean Journal of Internal Medicine·Hyemin JeongHoon-Suk Cha
Jan 27, 2015·Joint, Bone, Spine : Revue Du Rhumatisme·Florenzo IannoneGiovanni Lapadula
Jan 16, 2013·Asian Pacific Journal of Tropical Medicine·Feng LiuShu-Feng Li
Nov 27, 2014·Frontiers in Immunology·Elisa GremeseGianfranco Ferraccioli
Oct 14, 2016·European Journal of Clinical Investigation·Anais GardettePhilippe Dieudé
Dec 16, 2016·Pharmacogenomics·Rocío Prieto-PérezFrancisco Abad-Santos
Apr 4, 2018·International Journal of Rheumatic Diseases·Hyemin JeongHoon-Suk Cha
Aug 30, 2018·The British Journal of Dermatology·R B WarrenUNKNOWN PSORT Consortium and on behalf of the BADBIR Study Group
Jul 18, 2017·The Journal of Rheumatology·Sebastián E Ibáñez VodnizzaIrene E van der Horst-Bruinsma
Dec 17, 2015·The Journal of Rheumatology·Fiona MaasAnneke Spoorenberg
Jan 23, 2013·European Journal of Gastroenterology & Hepatology·Mahesh BhalmeSimon Campbell
Jun 5, 2018·Journal of Pharmaceutical Health Services Research : an Official Journal of the Royal Pharmaceutical Society of Great Britain·Jessica A WalshYujin Park
Dec 23, 2017·Frontiers in Immunology·Daniela FrascaRoberto Paganelli
May 23, 2018·Inflammatory Bowel Diseases·Kenneth Grønkjær MadsenJens Kjeldsen
Jul 21, 2017·Arthritis Research & Therapy·Raphael MicheroliUNKNOWN Rheumatologists of the Swiss Clinical Quality Management Program
Mar 23, 2019·Rheumatology International·José Miguel Senabre GallegoUNKNOWN AIRE-MB Group
Mar 17, 2016·The Journal of Rheumatology·Balahan MakayErbil Ünsal
Mar 7, 2021·International Journal of Molecular Sciences·Daniela FrascaBonnie B Blomberg
Mar 29, 2021·Zeitschrift für Rheumatologie·Ulf Müller-LadnerAndreas Schäffler

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

Angelman Syndrome

Angelman syndrome is a neurogenetic imprinting disorder caused by loss of the maternally inherited UBE3A gene and is characterized by generalized epilepsy, limited expressive speech, sleep dysfunction, and movement disorders. Here is the latest research.